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Resistance to cytotoxic agents has long been known to be a major limitation in the treatment of human cancers. Although
many mechanisms of drug resistance have been identified, chemotherapies targeting known mechanisms have failed to lead to
effective reversal of drug resistance, suggesting that alternativemechanisms remain undiscovered. Previouswork identifiedmidkine
(MK) as a novel putative survival molecule responsible for cytoprotective signaling between drug-resistant and drug-sensitive
neuroblastoma, osteosarcoma and breast carcinoma cells in vitro. In the present study, we provide further in vitro and in vivo
studies supporting the role of MK in neuroblastoma cytoprotection. MK overexpressing wild type neuroblastoma cells exhibit a
cytoprotective effect on wild type cells when grown in a co-culture system, similar to that seen with doxorubicin resistant cells.
siRNA knockdown of MK expression in doxorubicin resistant neuroblastoma and osteosarcoma cells ameliorates this protective
effect. Overexpression of MK in wild type neuroblastoma cells leads to acquired drug resistance to doxorubicin and to the related
drug etoposide. Mouse studies injecting various ratios of doxorubicin resistant or MK transfected cells with GFP transfected wild
type cells confirm this cytoprotective effect in vivo. These findings provide additional evidence for the existence of intercellular
cytoprotective signals mediated by MK which contribute to chemotherapy resistance in neuroblastoma.
1. Introduction
Drug resistance poses a major obstacle in the treatment of
human cancers. Several mechanisms responsible for resis-
tance to chemotherapy have previously been described.
Drug-resistant cellsmay express one ormore energy-depend-
ent transporters like the multidrug resistance gene (mdr1)
which detect and eject anticancer drugs from cells [1, 2].
Mechanisms including secondary mutations in drug targets
or parallel pathways, insensitivity to drug-induced apoptosis
[3, 4], and induction of drug-detoxifying proteins also play
a role in acquired multidrug resistance (MDR). Numerous
attempts have beenmade to target these pathways and reverse
drug resistance. Although some attempts were successful in
vitro, these strategies were not successfully implemented in
vivo [5]. These data suggest there are additional, perhaps
unknown mechanisms, which need to be identified and tar-
geted for successful reversal or prevention of drug resistance.
Our laboratory has hypothesized a cytoprotective rela-
tionship between drug-resistant and drug-sensitive cells
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within drug-resistant tumors. We previously demonstrated
a mechanism of cytoprotective signaling between drug-re-
sistant and drug-sensitive neuroblastoma, osteosarcoma, and
breast cancer cells [6]. A cytokine cDNA array identified
midkine (MK) as significantly upregulated in drug-resistant
cells and MK consequently was confirmed to play a key role
in cytoprotection.
MK is a retinoic acid-induced neurotrophic factor. It is
a small cysteine-rich protein which belongs to the family
of heparin-binding proteins and is highly expressed during
midgestation in mouse embryogenesis. MK is integral to
neuronal development, migration, and neurite outgrowth
[7]. MK has been reported to play important roles in the
survival, growth, and migration of many cells, which may
contribute to oncogenesis and tumor progression. Enriched
MK expression has been demonstrated in cancers including
Wilms’ tumor, neuroblastoma, esophageal, pancreatic, lung,
and breast cancers while its expression is usually low in
normal human adult tissues [8–10]. In addition, evidence
suggests that increased expression of MK is associated with
poor prognosis in oral squamous cell carcinoma [11], neurob-
lastoma [12, 13], and bladder carcinoma [14].
Recently, several other studies have implicated MK in
drug resistance. Kang et al. used microarray analysis to assess
global gene expression in gastric cancer cell lines with
acquired drug resistance to 5-fluorouracil, doxorubicin, and
cisplatin (CDDP) [15].They reported thatMK expressionwas
enhanced in all drug-resistant cell line studies, suggesting
an important role in drug resistance. Qi et al. reported that
MK had cytoprotective activity, preventing CDDP-induced
apoptotic cell death through enhancement ofBcl-2 expression
in both murine kidney and cultured Wilms’ tumor cells
(G401 cells) [16]. These findings support our hypothesis that
intercellular cytoprotective signals, such as the one mediated
byMK, originate from cells with acquired drug resistance and
protect neighboring drug-sensitive cells, thus contributing to
chemotherapy resistance.
In the present study, the relationship betweenMK expres-
sion and drug resistance has been further investigated. Spe-
cial emphasis was placed on determining whether the cyto-
protective action of MK observed in vitro also occurs in vivo
using a murine model xenograft.
2. Materials and Methods
2.1. Reagents. All materials utilized in this study were pur-
chased from the following companies: Dulbecco’s modified
Eagle’s medium (DMEM) (Mediatech, Inc., Pittsburgh, PA);
fetal bovine serum (FBS) (HyClone, Logan, UT); doxoru-
bicin; 3-(4,5-dimethyl-2-thiazolyl)2,5-diphenyl tetrazolium
bromide (MTT) (Sigma, St Louis, MO); antibodies to mid-
kine (R&D Systems, Minneapolis, MN); antibody to 𝛽-actin
(Sigma, St. Louis, MO); secondary antibodies conjugated
to horseradish peroxidase (Promega Corporation, Madison,
WI); enhanced chemiluminescence reagents (Pierce Corp.,
Rockford, IL); Immobilon-P transfer membrane for western
blot (Millipore, Bedford, MA); nitrocellulose membranes
(Bio-Rad Laboratories, Inc, Hercules, California); TUNEL
assay kit (Roche Diagnostics Corporation, Indianapolis, IN).
2.2. Cell Culture and Generation of Doxorubicin Resistant Cell
Lines. Human neuroblastoma SK-N-SH and osteosarcoma
SJSA-1 (OSA) cells were purchased from ATCC (Rockville,






(SK-N-SH WT) cells was determined using the MTT assay.
The generation of doxorubicin resistant SK-N-SH cells (SK-
N-SH DoxR) was achieved by incubating parental cell lines
with incrementally increasing concentrations of doxorubicin
ranging from 10−9 to 10−6M over a period of 6 months. Cells
were deemed resistant after surviving 10 passages in a dox-
orubicin concentration of 10−6M, approximately 2 Log above
the IC
50
of the parental cell line. Cells were then continuously
selected in DMEM containing doxorubicin 10−6M. SK-N-SH
GFP cells (SK-N-SHGFP-WT)were generated using pLPCX-
EGFP retrovirus and selected with puromycin. Human MK
overexpressed SK-N-SH cells (SK-N-SHHMK) were derived
as previously reported [6].
2.3. Co-Culture Cytoprotective Assay. The cytoprotective
effect of SK-N-SH DoxR cells on SK-N-SH WT cells was
quantitatively evaluated using a co-culture system. The Fal-
con Cell Culture Insert System (BD Falcon, Franklin Lakes,
NJ) was used to allow SK-N-SH WT cells to be co-cultured
with either SK-N-SH WT or SK-N-SH DoxR cells. For each
co-culture setup, the two cell types were grown in separate
compartments without physical contact. Small molecules
were able to diffuse through the media between compart-
ments by traversing a 0.4 𝜇m membrane. Cells were seeded
and grown for 72 hours prior to being treated with doxoru-
bicin at concentrations of 0, 10−7, or 10−6M for 24 hours.
Cell survival was then assayed using trypan blue staining and
manual cell counting.
2.4. Western Blot Analysis. Whole cell lysates, culture medi-
um, or cell membranes were isolated and subjected to elec-
trophoresis. Whole cell lysates were isolated from cells grown
to 80% confluence in 25 cm2 flasks. Cells were collected
and lysed in a lysis buffer composed of 50mM HEPES
pH 7.4, 150mM NaCl, 100mM NaF, 1mM MgCl
2
, 1.5mM
EGTA, 10% glycerol, 1% Triton X100, 1𝜇g/mL leupeptin,
and 1mM phenyl-methyl-sulfonyl-fluoride. These whole cell
lysates were subjected to sonication. Culture medium was
collected from cells grown to 80% confluence in 25 cm2 flasks.
Initially grown in DMEM supplemented with 10% FBS, cells
were then serum starved for 48 hours in 2mL of low fetal
bovine serum culture medium. Cultured medium was then
collected and frozen at −20∘C prior to being subjected to
western blot. Cell membranes were isolated using a well-
established protocol [17].
Protein concentrations were determined for whole cell
lysates and cell membrane fractions, and equal quantities
of protein were separated by electrophoresis on a 4–20%
SDS-PAGE gel and transferred to nitrocellulose membranes.
The volume of medium loaded on the gel was normalized
based on cell count in the flask prior to medium collection.
Nitrocellulose membranes were incubated with antibodies
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for proteins of interest (anti-MK, anti-P-glycoprotein or 𝛽-
actin) and subsequently incubated with appropriate sec-
ondary antibody conjugated to horseradish peroxidase. Pro-
tein expression was then detected using chemiluminescence.
2.5. siRNA Design and Transfection. Human MK siRNA was
synthesized by Dharmacon (Lafayette, CO). The nucleotide
sequences for the human MK genes were obtained from the
NCBI sequence viewer program.The human MK siRNA was
based on sequence 229 to 249 and consisted of the following
nucleotides: 5󸀠-AAGAAGGAGTTTGGAGCCGAG-3󸀠. On
the day before transfection, 3 × 105 cells were seeded into
6-well plates and grown in 2.5mL of DMEM supplemented
with 10% fetal bovine serum. After 24 hours in culture, 25 𝜇L
of 20 𝜇M stock solution of siRNA duplexes was transfected
into cells using GeneSilencer siRNA transfection reagent
according to the manufacturer’s protocol (Gene Therapy
Systems, San Diego, CA). Cells were maintained in culture
for an additional 96 hours beforemeasuring expression of the
silenced molecules by western blot and ELISA assay.
2.6. Cell Proliferation Assay. Cell proliferation was assessed
using the MTT assay. Cells were seeded in 96 well plates and
incubated with logarithmic concentrations of doxorubicin,
ranging from 10−9 to 10−5M. Cell proliferation was quan-
titatively estimated by use of a colorimetric assay using 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT). MTT (10 𝜇L of 5mg/mL solution) was added to
each well of the plate and incubated for 4 hours at 37∘C.
The cells were then solubilized by the addition of 100 𝜇L of
10% SDS/0.01mmol/L HCl and incubated for 15 hours at
37∘C. The absorbance of each well was determined in an
ELISA plate reader using an activation wavelength of 570 nm
and a reference wavelength of 650 nm. Cell viability in the
presence of different doses of doxorubicin was determined by
comparison with untreated control cells.
2.7. In Vivo Studies. The animal protocol used in this study
was approved by the Animal Care and Use Committee of
the Lurie Children’s Hospital of Chicago Research Center
(no. 2006-29). Severe combined immunodeficiency (SCID)
or nudemice (Charles River Laboratories,Wilmington,MA),
approximately 4–6 weeks of age and weighing approximately
30 g received subcutaneous (SC) tumor implants performed
using various ratios of GFP expressing SK-N-SH wild type
cells (SK-N-SH GFP-WT) and SK-N-SH doxorubicin drug-
resistant cells (SK-N-SH DoxR) or SK-N-SH HMK (SK-N-
SH HMK) cells with a total of 106 cells in 100 𝜇L per implant.
GFP-WT/DoxR implants were performed at ratios as follows:
(a) SKN-SHGFP-WTonly, (b) 1 : 1 ratio of SK-N-SHGFP-WT
and SK-N-SH DoxR, (c) 1 : 2 ratio of SK-N-SH GFP-WT and
SK-N-SH DoxR, and (d) 1 : 4 ratio of SK-N-SH GFP-WT and
SK-N-SHDoxR. GFP-WT/HMK implants were performed at
ratios as follows: (a) SKN-SH GFP-WT only, (b) 1 : 1 ratio of
SK-N-SH GFP-WT and SK-N-SH HMK, (c) 1 : 2 ratio of SK-
N-SHGFP-WT and SK-N-SHHMK, and (d) 1 : 4 ratio of SK-
N-SH GFP-WT and SK-N-SH HMK.
When tumors were palpable, the animals were challenged
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Figure 1: Co-culture effect on cellular response to doxorubicin.
Wild type human neuroblastoma (SK-N-SH WT) cells co-cultured
with SK-N-SH WT cells (WT/WT) were compared to co-cultures
of SK-N-SH WT cells with doxorubicin resistant cells (SK-N-SH
DoxR) (WT/DoxR). Co-cultures were treated with and without
doxorubicin at 10−7 or 10−6M for 48 hours. Surviving cells were
quantified using trypan blue staining. The cell survival ratio rep-
resents the number of live WT cells in the drug-treated co-culture
divided by the number live cells in the untreated (control), ∗𝑃 <
0.001.
injections, each separated by 3 days, were performed. Mice
were weighed and checked for clinical signs of drug toxi-
city and lethality. Tumor measurements were made with a
caliper three times weekly for 3 to 4 weeks and converted
to tumor volume by using the formula 𝑊 × 𝐿2/2. Tumor
growth curves were generated. At 4 weeks after implant, the
mice were euthanized and the tumor area was measured
after aseptic excision from the host. Tissue specimens were
processed and stained with hematoxylin and eosin to assess
tumor morphology and GFP expression.
2.8. TUNEL Assay. Terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) allows detection of
genomic DNA cleavage which occurs during apoptosis by
incorporating fluorescein labels in nucleotide polymers.
TUNEL was used to detect apoptotic cells amongst SK-N-
SH GFP-WT cells grown in co-culture with SK-N-SH WT,
DoxR, or HMK cells. Labeling was quantified using fluores-
cence microscopy (in situ Cell Death Detection kit; Roche
Molecular Biochemicals, Indianapolis, IN).The total number
of GFP-WT cells per high-powered field was counted using
the 40x objective. TUNEL-positive nuclei were manually
counted using the same power objective.
2.9. Immunohistochemistry for Midkine. After obtaining
Internal Review Board approval (IRB# 2010-14080), pediatric
patients treated for neuroblastoma from January 1999 to
December 2008 at a free-standing, tertiary care children’s
























































Figure 2: Effect of midkine overexpression on wild type cell survival. A midkine overexpressing SK-N-SH cell line (SK-N-SH HMK) was
created as previously described [6]. (a) Midkine expression in the medium of wild type (WT), doxorubicin resistant (DoxR), and HMK
cells were analyzed using western blot. SK-N-SH WT, DoxR, and HMK were cultured in 25 cm flasks to 80% confluence. Medium was then
exchanged for 2mL of low fetal bovine serum culture medium and cultured for an additional 48 hours. Cultured medium was then collected
and frozen at −80∘C prior to being subjected to western blot.The volume of medium loaded on the gel was normalized based on cell count in
the flask prior tomediumcollection. Cellmembraneswere isolated through awell-established protocol.Wehave previously demonstrated that
midkine transfected cells (HMK) have acquired some doxorubicin resistance [6]. The MTT cell survival assay was performed to determine
if SK-H-SH HMK cells have acquired resistance to other chemotherapeutic drugs including (b) etoposide and (c) cisplatin. (d) SK-N-SH
WT, DoxR, and HMK cells were treated with or without doxorubicin at 10−7M for 24 hours prior to collection of cell lysates. Proteins were
extracted and probed using western blot for Pgp and 𝛽-actin.
completed therapy before December 2008 and who no longer
require biopsy tissue for diagnostic purposes were included
in the study. Medical records were reviewed for the following
clinical features: age at diagnosis, pathology features (favor-
able versus unfavorable), N-MYC amplification status, tumor
stage, and outcome (mortality). Paraffin embedded tissue
samples were collected from the pathology bank, and slides
were created.
Formalin-fixed paraffin embedded slides were dewaxed
in xylene and hydrated through a graded series of alcohols.
Endogenous peroxidases were blocked with a 3% hydrogen
peroxide treatment; antigen retrieval was performed by
boiling for 20 minutes in a 0.01M sodium citrate (pH 6)
solution, and endogenous biotin blocked using Avidin/Biotin
Blocking Kit (Vector Labs, SP-2001). Slides were incubated
overnight in the primary antibody for MK (1 : 250 dilution).
Following incubation with the appropriate biotin-labeled
secondary antibodies, the labeled antigens were visualized
by streptavidin-biotin (Vectastain Elite ABC kit; Vector
Laboratories) followed by ImmunoPure Metal Enhanced
DAB Substrate (Thermo Scientific) and counterstained with
hematoxylin (Richard-Allen Scientific).
Cytoplasmic and nuclear staining were scored on a scale
of none (0), low (1+), medium (2+), and high (3+) on a
blinded basis. When both prechemotherapy and postchem-
otherapy biopsy specimens were available, expression of
MK was compared to determine if MK expression changes








































































Figure 3: Effect of midkine overexpression on cellular response to doxorubicin in co-culture conditions. (a) GFP-transfected wildtype SK-
N-SH cells (GFP-WT) were co-cultured with wild type (WT), doxorubicin resistant (DoxR), or human midkine overexpressing SK-N-SH
cells (HMK), incubated with (+) or without (−) doxorubicin at 10−7M for 48 hours. Photographs were taken using fluorescence microscopy.
(b) The viability percentage of fluorescent cells (GFP-WT) after each treatment was determined through Hoechst 33342 staining and cell
counting. Data represent an average of three independent determinations +/− SE.
chemotherapy. Expression ofMKwas also compared between
patients by age at diagnosis (<1 year versus >1 year), stage,
N-MYCamplification status (amplified versus nonamplified),
histology (favorable versus unfavorable), and survival status.
2.10. Statistical Analysis. Data are expressed as means ± SE.
Differences in measured variables between the experimental
and control groups were assessed using Student’s 𝑡-test. Sta-
tistical calculations were performed using the Statview statis-
tical package (Abacus Concepts, Berkeley, CA). 𝑃 < 0.05 was
considered statistically significant.
3. Results
3.1. Protection of Drug-Sensitive Cells by Drug-Resistant Cells
in Coculture Is Mediated by Midkine. Earlier studies revealed
that MK was able to exert a survival function in a variety of
cellular systems and against various stimuli, suggesting that it
could be associated with drug resistance [6]. Overexpression
of MK in doxorubicin-resistant SK-N-SH human neurob-
lastoma cell lines confirmed this assumption and suggested
that it may play a role as a cytoprotective signal between
drug-resistant and drug-sensitive cells. We have previously
shown that conditioned medium from doxorubicin resistant
cells exerts a protective effect on their parental wild type cell
line against drug toxicity [6]. Further co-culture experiments
were performed to study its cytoprotective role. Cells cannot
move between chambers in the co-culture setup; however,
small proteins such as MK can freely diffuse between cham-
bers through the co-culture membrane (0.4 𝜇M). Cytopro-
tective activity was quantitatively determined by comparing
the survival of wild type, drug-sensitive neuroblastoma SK-
N-SH cells (SK-N-SH WT) co-cultured with either doxoru-
bicin resistant (SK-N-SH DoxR, WT/DoxR) or doxorubicin
sensitive (SK-N-SHWT,WT/WT) cells for 72 hours and then
treated with doxorubicin at concentrations of 10−7 and 10−6M
for 48 hours (Figure 1). The cell survival ratio of SK-N-SH
WT cells co-cultured with SK-N-SH WT cells (WT/WT) in
this system was 0.23 compared to 0.37 for co-cultures of SK-
N-SH WT and SK-N-SH DoxR cells (WT/DoxR) incubated
with 10−7M doxorubicin (𝑃 < 0.001); the cell survival ratio
was 0.11 for WT/WT and 0.21 for WT/DoxR cells incubated
with 10−6M doxorubicin (𝑃 < 0.001). Thus, coincubation of
drug-sensitive cells with drug-resistant cells was associated
with an increase in cell survival ratio significantly above that
observed with drug-sensitive cells.
These findings demonstrate that ligands secreted by dox-
orubicin resistant human neuroblastoma cells impart a cyto-
protective effect on drug-sensitive cells, providing further
support for the humoral mediation of resistance to chemo-
therapy. In order to confirm that MK was the molecule
responsible for this protective effect, we created a MK over
expressing cell line (SK-N-SHHMK) as previously described





















































































































Figure 4: Effect of midkine siRNA on cytoprotection. (a) ELISA assay and (b) western blot were used to confirm decreased expression
of midkine in doxorubicin resistant SK-N-SH cells (DoxR) treated with midkine. Culture medium from SK-N-SH wild type (WT), DoxR,
DoxR cells treated with scramble sequence siRNA (DoxR-scramble), and DoxR cells treated with siRNA to midkine (DoxR-si-midkine) was
harvested after growth for 96 hours. (c) SK-N-SH WT cells were grown in co-culture with WT, DoxR, and DoxR-scramble or DoxR-si-
midkine cells. Co-cultures were incubated for 48 hours with or without doxorubicin at 10−7M and 10−6M. SK-N-SH WT cell survival was
then quantified through cell counting after staining with trypan blue. Data represents the average of 4 experiments +/− SE. (d) OSAWT cells
were grown in co-culture with OSAWT, DoxR, and DoxR-scramble or DoxR-si-midkine cells. Co-cultures were incubated for 48 hours with
or without doxorubicin at 10−7Mand 10−6M.OSAWT cell survival was then quantified through cell counting after staining with trypan blue.
Data represents the average of 4 experiments +/− SE.
in the cell membrane fraction and culture medium for
these SK-N-SH HMK cells as seen in the SK-N-SH DoxR
cells (Figure 2(a)). The MTT cell survival assay previously
demonstrated increased survival for a given concentration of
doxorubicin for the SK-N-SH HMK cell relative to SK-N-SH
WT cell, but not to the extent of SK-N-SH DoxR cells [6].
Here, the MTT assay also demonstrated that the SK-N-SH
HMKcell line displayed resistance to etoposide (Figure 2(b)).
The SK-N-SH WT, DoxR, and HMK cell lines were equally
susceptible to cisplatin (Figure 2(c)).
Themdr1 gene is known to be an inducible drug resistance
gene [18]. To rule out a protective role for mdr1, the gene
for p-glycoprotein (Pgp) in the SK-N-SH HMK cell line, we
compared Pgp expression levels in all aforementioned three
cell lines with or without doxorubicin (10−7M) treatment
using western blot analysis. Figure 2(d) demonstrates that
Pgp is expressed only in SK-N-SH DoxR cells and not in SK-
N-SH WT or HMK cells either at baseline or when treated
with doxorubicin. These data suggest that mdr1 does not
contribute to the self-protective effect demonstrated in SK-
N-SH HMK cells.
Previous co-culture experiments using GFP-transfected
wild type SK-N-SH cells (GFP-WT) co-cultured with either
SK-N-SH WT cells or DoxR cells confirmed the cytopro-
tective effect of SK-N-SH DoxR cells suggesting humoral
protection. In order to confirm that MK was the molecule
responsible for this effect, these co-culture experiments were
repeated using the MK overexpressing cell line (SK-N-SH
HMK). Co-cultures were grown using SK-N-SH GFP-WT


































Figure 5: Effect of midkine siRNA on doxorubicin resistant cellular
response to doxorubicin. siRNA was used to knock down midkine
expression in doxorubicin resistant SK-N-SH cells (DoxR) to deter-
mine if loss of midkine expression results in restoration of drug
sensitivity in the DoxR cells. Wild type (WT), DoxR, DoxR cells
treated with scramble sequence RNA (DoxR-scramble) and SK-N-
SH DoxR cells treated with siRNA to midkine (DoxR-si-midkine)
were cultured with or without doxorubicin at 10−7M and 10−6M
for 24 hours. Cell survival was assayed using trypan blue and cell
counting. Data represents the average of 4 experiments +/− SE.
resistant cells (SK-N-SH DoxR), or human MK overexpress-
ing SK-N-SH cells (SK-N-SHHMK). Cells were grown in co-
culture for 48 hours then incubated with (+) or without (−)
doxorubicin (10−7M) for 48 hours. Inserted SK-N-SH WT
cells were then stained using Hoechest 33342 to determine
cell viability. As seen in Figures 3(a) and 3(b), the GFP
cells alone retained their original sensitivity to doxorubicin;
however, when co-cultured either with nonfluorescent dox-
orubicin resistant cells or HMK transfected cells and treated
with doxorubicin, the number of viable cells per defined
area was higher than that with the drug-sensitive cells alone.
These data support the hypothesis that MK is responsible
for a humoral cytoprotective effect of drug-resistant cells on
nearby drug-sensitive cancer cells.
3.2. siRNA to Midkine Abolishes the Protective Effect of Drug-
Resistant Cells in Co-Culture with Drug-Sensitive Cells. To
further investigate the cytoprotective function of MK, we
set out to determine if inhibition of MK secretion reversed
or reduced the cytoprotective action exerted by doxorubicin
resistant neuroblastoma cells upon wild type, drug-sensitive
cells. siRNA to MK was used to knock down MK expression
in doxorubicin resistant cells. ELISA (Figure 4(a)) and west-
ern blot (Figure 4(b)) confirmed decreased expression ofMK
in doxorubicin resistant cell culture medium when treated
with siRNA to MK.
SK-N-SH WT cells (Figure 4(c)) or OSA cells
(Figure 4(d)) were grown in co-culture with their respective
WT cells, DoxR cells, DoxR cells treated with scramble
sequence siRNA, or DoxR cells treated with MK siRNA.
Co-cultures were untreated or treated with doxorubicin (10−7
or 10−6). The results demonstrate that drug-resistant cells
transfected with MK siRNA no longer exert a cytoprotective
effect. The scramble siRNA exerted a very limited effect on
cytoprotection, and only at a doxorubicin concentration of
10−7M. A parallel study carried out with pleiotrophin siRNA
did not affect the cytoprotective activity of doxorubicin
resistant cells on wild neuroblastoma cells (data not shown).
These data utilizing both a neuroblastoma cell line and an
osteosarcoma cell line suggest this phenomenon may be
generalized across multiple tumor types. Collectively, these
findings support the conclusion that MK plays a dominant
role in the cytoprotection induced by drug-resistant cancer
cells.
3.3. Midkine Is Partially Responsible for Drug Resistance
in Drug-Resistant Cells Themselves. We have shown that
induced expression ofMK inwild type SK-N-SH cells confers
a resistance to doxorubicin. We sought to determine if
MK plays a self-protective effect in doxorubicin resistant
cells themselves. We used MK siRNA to knock down MK
expression in doxorubicin resistant (SK-N-SH DoxR) cells.
Cells were either untreated or treated with doxorubicin (10−7
and 10−6 for 24 hr) (Figure 5). When compared with SK-N-
SHDoxR cells untreatedwith siRNAor treatedwith scramble
sequence siRNA, those treated with siRNA to MK had drug
sensitivity partially restored. These data suggest MK plays a
self-protective role in drug-resistant cells in addition to its
humoral protective effect on nearby otherwise drug-sensitive
cells.
3.4. Doxorubicin Resistant Cells andMidkine TransfectedWild
Type Cells Confer Cytoprotection In Vivo. To prove that drug-
resistant cells confer a humoralmediated cytoprotective effect
on drug-sensitive cells in vivo, we assessed the toxicity of dox-
orubicin in SCIDmice bearing xenografts with varying ratios
of drug-resistant and drug-sensitive neuroblastoma cells.
Mice were injected with 106 mixed SK-N-SH GFP-WT cells
and SK-N-SHDoxR (∼100 timesmore resistant than parental
drug-sensitive cells) in ratios from 1 : 0 to 1 : 4. When the
tumors became palpable,mice received three intra-peritoneal
drug injections of doxorubicin (2.5mg/kg) every 3 to 4 days
thereafter. Tumor measurements were made with a caliper
three times weekly for 3 to 4 weeks and converted to tumor
volume by using the formula 𝑊 × 𝐿2/2. Figure 6(a) shows
that injections with GFP-WT :DoxR ratios of 1 : 2 and 1 : 4
produced larger tumors than the control (SK-N-SH/GFP cells
alone, 1 : 0) and 1 : 1 ratio injections. A TUNEL assay was
also performed on these tumor specimens to assess for the
degree of apoptosis present (Figure 6(b)). As the ratio of SK-
N-SH DoxR to SK-N-SH GFP-WT increased, the percent
of apoptotic cells in the GFP cells decreased under UV
florescencemicroscopy.These data confirm that in the in vivo
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SK-N-SH GFP-WT : HMK
(c)
Figure 6: Effect of midkine cytoprotection on growth of wild type human neuroblastoma tumors in vivo. Mice were injected with drug-
sensitive humanneuroblastoma cells (SK-N-SHGFP-WT) and (a) drug-resistant humanneuroblastoma cells (SK-N-SHDoxR) or (b)midkine
transfected cells (SK-N-SH HMK) at various ratios (GFP-WT :DoxR or GFP-WT :HMK). Once the tumors were palpable, the mice received
injections of doxorubicin (2.5mg/kg) intraperitoneally every 3 days for a total of 3 doses. Tumor volumes were measured every 3 days for
up to 3 weeks. Tumor growth curves in the different groups were generated. Each data point in the growth curve represents the mean of 7
determinations ± SE. ∗𝑃 < 0.05; ∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001. (c and d) Apoptotic GFP-WT cells were measured by TUNEL assay in tumor
sections. The histogram represents a summary data.
a cytoprotective (antiapoptosis) effect on neighboring drug-
sensitive cells which allows them to grow despite drug treat-
ment. In order to confirm that MK was the agent responsible
for this cytoprotective effect in vivo, these experiments were
repeated injecting various ratios of SK-N-SH GFP-WT and
MK transfected (SK-N-SH HMK) cells subcutaneously in
nude mice with similar results (Figure 6(c)).
3.5. Midkine Expression Is Enriched in Human Tissue Samples
after Treatment. MK expression has previously been impli-
cated as a poor prognostic indicator in oral squamous cell
carcinoma [11], neuroblastoma [12, 13], and bladder carci-
noma [14]. We sought to determine whether a correlation
exists between MK expression and prognostic indicators for
neuroblastoma by evaluating the expression of MK in human
neuroblastoma tissue samples (Figure 7 and Table 1). After
nuclear and cytoplasmic scoring, we found no correlation,
in either pretreatment or posttreatment specimens, between
MK expression and neuroblastoma stage, N-MYC status, his-
tology (favorable versus unfavorable), age <1 year, or survival.
We also compared the expression of MK in pretreatment
specimens with posttreatment specimens with the hypothesis
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Table 1: Correlation of midkine staining in human tissues with prognostic indicators.
Nuclear score Cytoplasmic score
Prechemo 𝑃 Postchemo 𝑃 Prechemo 𝑃 Postchemo 𝑃
Stage 0.46 0.16 0.23 0.22
I 3.0 ± 0.0 3.0 ± 0.0 1.3 ± 0.9 0
II 3.0 ± 0.0 3.0 ± 0.0 0.0 ± 0.0 3.0 ± 0.0
III 1.8 ± 1.1 2.0 ± 1.0 0.0 ± 0.0 2.8 ± 0.4
IV 2.1 ± 1.2 1.0 ± 1.0 1.0 ± 1.1 2.0 ± 1.4
N-MYC Status 0.86 0.41 0.48 0.26
Nonamplified 2.2 ± 1.2 1.8 ± 1.2 0.8 ± 1.1 1.8 ± 1.3
Amplified 2.3 ± 0.9 1.0 ± 0.0 1.2 ± 1.2 3 ± 0
Histology 0.49 0.34 0.77 0.51
Favorable 2.4 ± 0.8 2.0 ± 1.0 0.8 ± 1.0 3.0 ± 0.0
Unfavorable 1.9 ± 1.4 1.3 ± 1.1 1.0 ± 1.2 2.3 ± 1.3
Age 0.17 0.20 0.22 0.90
<1 year 1.9 ± 1.4 1.3 ± 1.2 1.2 ± 1.2 2.1 ± 1.4
>1 year 2.6 ± 0.7 2.2 ± 1.0 0.6 ± 0.9 2.2 ± 1.2
Survival status 0.64 0.79 0.33 1
Survivor 2.1 ± 1.2 1.5 ± 1.1 0.8 ± 1.1 2.3 ± 1.1
Nonsurvivor 2.4 ± 1.2 1.3 ± 1.1 1.4 ± 1.2 2.3 ± 1.3
Table 2: Midkine expression prechemotherapy compared to postchemotherapy.
Nuclear Score Cytoplasmic score
Pre-chemo Post-chemo 𝑃 Pre-chemo Post-chemo 𝑃
All biopsies∗ 2.3 ± 1.1 1.7 ± 1.2 0.15 0.9 ± 1.1 2.2 ± 1.3 0.005
Matched biopsies∗∗ 2.1 ± 1.3 1.9 ± 1.3 0.74 0.4 ± 0.8 2.3 ± 1.2 <0.001
∗Comparison based on 20 prechemotherapy biopsies and 12 postchemotherapy biopsies.
∗∗Comparison based only on the 10 patients with matched pre- and postchemotherapy biopsies available for analysis.
that MK expressing, drug-resistant tumor cells would be
enriched in posttreatment specimens (Table 2). Histologic
scoring revealed that MK expression was enriched in the
cytoplasm of posttreatment specimens when compared to
pretreatment specimens (𝑃 < 0.001). These data show that
MK is enriched in the cytoplasm of posttreatment tumor
specimens, although its expression may not correlate with
survival or with prognostic indicators.
4. Discussion
In 1988, theMuramatsu group first describedmidkine as a 13–
15 KDheparin binding polypeptide present in embryonal car-
cinoma cells which acts to enhance neuronal cell survival and
stimulate neurite extrusion [19]. Midkine has subsequently
been found to be overexpressed in a number of malignant
tumors [8–10]. Midkine has been found to exert a survival
function in a variety of cell types and against various stimuli,
suggesting a potential role in drug resistance [16, 20].
Our laboratory has demonstrated that an intercellular
crosstalk occurs between cells that have acquired a drug
resistance phenotype and neighboring drug-sensitive tumor
cells [6]. Communication between drug-resistant cells by
secretion of survival factors, such as midkine, is postulated
to protect cells in the surrounding environment and enable
survival of the tumor as a whole. We previously showed
that wild type human neuroblastoma cells treated with con-
ditioned medium from doxorubicin resistant cells become
more resistant to doxorubicin [6]. However, although mid-
kinewas found to be upregulated in this conditionedmedia, it
remained possible that any number of other secreted survival
factors could have contributed to the conferred resistance. To
verify this result and rule out other growth and/or survival
factors which may also contribute to the observed effect, a
co-culture systemwas used in the present study.Thebenefit of
this system is that it allowed drug-sensitive and drug-resistant
cells to grow in separate compartments without physical
contact but permitted the diffusion of secreted molecules
or drugs from one compartment to the other by travers-
ing the membrane. The results presented here demonstrate
thatmidkine transfected cells have almost the same ability for
cellular protection as those of drug-resistant cells through a
Pgp independent mechanism. This serves as direct evidence
of crosstalk between drug-resistant-and drug-sensitive cells
with midkine identified as being the protein involved in this
mechanism, allowing for conferred drug resistance.
Our in vitro and in vivo studies demonstrated a signif-
icant cytoprotective effect of doxorubicin resistant cells or
midkine expressing cells on wild type cells. This effect was
abolished when midkine expression was downregulated in
drug-resistant cells using siRNA. In accordance with our
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Figure 7: Immunohistochemistry for midkine in human neurob-
lastoma tissue samples. Prechemotherapy and postchemotherapy
patient neuroblastoma biopsy sampleswere collected and stained for
midkine. Midkine staining was scored using a 0 (negative), 1+
(weak staining), 2+ (moderate staining), and 3+ (strong staining)
scale on a blinded basis. Midkine staining was then correlated with
tumor stage, N-MYC amplification status, histology (favorable or
unfavorable), and survival. Biopsy scores were also evaluated for a
change in midkine staining prechemotherapy to postchemotherapy.
Shown here is a sample neuroblastoma histology slide stained for
midkine.
results, Takei et al. reported that inhibition of midkine
secretion and expression using siRNA in prostate cancer PC-
3 cells leads to significant suppression of tumor growth in a
xenograft model [21]. Dai et al. significantly suppressed the
growth of hepatocellular carcinoma in vitro and in vivo using
nanoliposomes packaged with antisense phosphorothioate
oligonucleotide targetingmidkine (MK-ASODN) [22].These
data suggest that inhibition of midkine may constitute a
useful therapeutic target.
Midkine expression is usually low in normal human
adult tissues.Wilms’ tumor, neuroblastoma, esophageal, pan-
creatic, lung, and breast cancers have all been shown to
have enriched MK expression [8–10]. In addition, increased
midkine expression is associated with poor prognosis in oral
squamous cell carcinoma [11], neuroblastoma [12, 13], and
bladder carcinoma [14]. Ikematsu et al. demonstrated that
plasma midkine levels in neuroblastoma patients correlated
significantly with prognostic indicators in neuroblastoma
including MYCN amplification, ploidy, tumor stage, and age
[13]. We were able to demonstrate an increase in cytoplasmic
midkine staining in postchemotherapy biopsy specimens
relative to prechemotherapy specimens. These data suggest
that midkine expression is induced or acquired during the
acquisition of drug resistance and support our in vitro
finding of increased midkine expression in neuroblastoma
cells which acquire drug resistance through long-term drug
exposure. Our histopathologic analysis did not demonstrate
a correlation of tumor midkine expression levels with prog-
nostic indicators. This finding however may be due to lack
of power with the small sample size of biopsy specimens
available for these investigations. It may also be due to MK
primary role as a secreted factor and therefore not present in
the immunohistochemistry results.
The exact mechanism by which midkine mediates drug
resistance remains poorly understood, but it is postulated that
midkine has anti-apoptotic (or antiautophagy) [23–25] and
proangiogenic activity [9, 26] promoting survival in human
tumors. Midkine was found to protect Wilms’ tumor cells
from cisplatin-induced apoptosis through Bcl-2 enhanced
expression [16]. In human pediatric rhabdoid tumor G401
cells, midkine activates the anti-apoptotic pathway mediated
by STAT1 and the Janus-activated kinases (JAKs) [27]. Mid-
kine has been shown to activate the survival pathway medi-
ated by Akt in cultured neurons leading to a neuroprotective
effect [23]. Furthermore, You et al. reported that midkine
is a NF-𝜅B-inducible gene which supports prostate cancer
cell survival [28]. Recently, Gu¨ngo¨r et al. [29] identified
an interaction between the Notch-2 receptor and midkine
in pancreatic ductal adenocarcinoma (PDAC) cells. They
found that MK-Notch-2 interaction activated Notch signal-
ing, upregulating NF-𝜅B inducing epithelial-mesenchymal
transition (EMT), and increased chemoresistance.
Perhaps the most intriguing questions regarding the anti-
apoptotic activity of midkine and other heparin binding
growth factors reside in determining potential sites of action
in the cell. Because midkine is secreted from drug-resistant
cells, the neighboring drug-sensitive cells must express a
receptor for midkine as well as the related signaling pathway.
By virtue of its apparent lack of specificity, midkine may
bind nonspecifically to and activate various receptors, lead-
ing to activation of more than one survival pathway and
thus increasing its chances tomediate cytoprotection. At least
four receptors, namely, N-syndecan [30], RPTPz [31], ALK
[24, 32] and LRP1 [33], have been proposed to mediate the
biological activities of midkine [33], and extensive studies
have been undertaken investigating the potential roles of
these pathways.
In summary, the evidence presented in this study con-
firms the existence of an intercellular cytoprotective signal
within drug-resistant tumors which allows phenotypically
drug-resistant tumor cells to protect nearby otherwise drug
sensitive cells. This humoral effect appears to be mediated
primarily by midkine, allowing protection of neighboring
cells from drug-induced killing. Future studies identifying
the pertinent midkine receptors and downstream signaling
pathways may identify novel tumor markers or therapeutic
targets.
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